# RZLT — Rezolute Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RZLT  
**Sources:** 17  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rzlt-rezolute-inc-catalysts-narrative-risks-10427

---

## Snapshot (as of the research date, ~2026-10-30/31)

Rezolute, Inc. (Nasdaq: RZLT) is a late-stage/clinical-stage rare-disease biopharmaceutical company headquartered in Redwood City, California, led by CEO Nevan Elam [[6]](https://ir.rezolutebio.com/news/detail/384/rezolute-reports-fourth-quarter-and-full-year-fiscal-2026-financial-results-and-provides-business-update), [[12]](https://www.marketbeat.com/stocks/NASDAQ/RZLT/), [[14]](https://stockanalysis.com/stocks/rzlt/). Its lead asset is ersodetug (RZ358), a fully human monoclonal antibody that binds an allosteric site on the insulin receptor to reduce the effects of excessive insulin; it is being developed for congenital HI and tumor HI [[8]](https://finance.yahoo.com/healthcare/articles/rezolute-reports-fourth-quarter-full-200500602.html), [[12]](https://www.marketbeat.com/stocks/NASDAQ/RZLT/), [[14]](https://stockanalysis.com/stocks/rzlt/). A secondary candidate, RZ402 (oral plasma kallikrein inhibitor for retinal vascular disease, e.g., diabetic macular edema), exists but is lower in the pipeline [[12]](https://www.marketbeat.com/stocks/NASDAQ/RZLT/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rzlt-rezolute-inc-catalysts-narrative-risks-10427 (free to sign up)._